Financial Review: Biofrontera (NASDAQ:BFRI) and Indaptus Therapeutics (NASDAQ:INDP)

Biofrontera (NASDAQ:BFRI) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Volatility and Risk

Biofrontera has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Earnings & Valuation

This table compares Biofrontera and Indaptus Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$34.07 million	0.26	-$20.13 million	($2.26)	-0.51
Indaptus Therapeutics	N/A	N/A	-$15.42 million	($1.71)	-0.49

Indaptus Therapeutics has lower revenue, but higher earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biofrontera and Indaptus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biofrontera	-36.31%	-565.73%	-96.64%
Indaptus Therapeutics	N/A	-177.27%	-141.06%

Institutional and Insider Ownership

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 0.2% of Biofrontera shares are held by company insiders. Comparatively, 29.5% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Biofrontera and Indaptus Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	0	0	1	0	3.00
Indaptus Therapeutics	0	0	2	0	3.00

Biofrontera currently has a consensus price target of $7.00, suggesting a potential upside of 503.45%. Indaptus Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 920.41%. Given Indaptus Therapeutics’ higher probable upside, analysts plainly believe Indaptus Therapeutics is more favorable than Biofrontera.

Summary

Indaptus Therapeutics beats Biofrontera on 9 of the 12 factors compared between the two stocks.

About Biofrontera

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.